GamaMabs Pharma Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Employees
  • 7
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $16.1M
Latest Deal Amount
  • Investors
  • 7

GamaMabs Pharma General Information

Description

Developer of optimized therapeutic antibodies designed for the treatment of cancer. The company's monoclonal antibodies have increased tumor cell killing properties which target anti-mullerian human receptors in ovarian cancer, thereby enabling physicians to treat unaddressed specific targets in gynecological cancers.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Primary Office
  • Centre Pierre Potier, 1 place Pierre Potier
  • ONCOPOLE entrée B, Cedex 1
  • 50624 Toulouse
  • France
+33 05 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

GamaMabs Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 15-Dec-2015 $16.1M 000.00 Completed Clinical Trials - Phase 1
2. Early Stage VC 03-Mar-2014 00.00 00.000 Completed Startup
1. Early Stage VC (Series A) 30-Sep-2013 $4.81M $4.81M Completed Startup
To view GamaMabs Pharma’s complete valuation and funding history, request access »

GamaMabs Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of optimized therapeutic antibodies designed for the treatment of cancer. The company's monoclonal antibodies
Drug Discovery
Toulouse, France
7 As of 2021
000.00
00000000000 000.00

000 0000

llum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
0000 000000000
Barcelona, Spain
00 As of 0000
0000
00000000000 0000

00000000

t, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. U
0000 000000000
Boston, MA
00 As of 0000
0000
00.00 0000-00-00
00000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GamaMabs Pharma Competitors (10)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ona Therapeutics Venture Capital-Backed Barcelona, Spain 00 0000 00000000000 0000
00000000 Venture Capital-Backed Boston, MA 00 0000 00000000000 0000
00 000000000000 Formerly VC-backed Durham, NC 000 00000 000000 - 000 00000
0000000 000000 Venture Capital-Backed Barcelona, Spain 00 0000 000000000000 0000
0000000 000000 Venture Capital-Backed Stockholm, Sweden 00 000.00 0000000000 0 000.00
You’re viewing 5 of 10 competitors. Get the full list »

GamaMabs Pharma Patents

GamaMabs Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3789401-A1 Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers Pending 03-Sep-2019 00000000000 00
US-20170035903-A1 Antibodies, antibody drug conjugates and methods of use Granted 07-Aug-2015 000000000000 0
US-10509035-B2 Antibodies, antibody drug conjugates and methods of use Active 07-Aug-2015 000000000000 00
EP-3331569-A1 Antibodies, antibody drug conjugates and methods of use Pending 07-Aug-2015 000000000000
FR-3020063-A1 Anti-her4 human antibody Pending 16-Apr-2014 C07K16/32
To view GamaMabs Pharma’s complete patent history, request access »

GamaMabs Pharma Executive Team (5)

Name Title Board Seat Contact Info
Stephane Degove Chief Executive Officer, Managing Director, Chief Financial Officer and Board Member
Jean-Marc Barret Ph.D Head of Pharmacology & Pharmacology Manager
Jean-François Prost MD Chief Medical and Scientific Officer, Board Member and Vice President of Research and Development and Strategy
Thierry Hercend Ph.D Chairman
You’re viewing 4 of 5 executive team members. Get the full list »

GamaMabs Pharma Board Members (10)

Name Representing Role Since
Aneta Sottil Andera Partners Board Member 000 0000
François Thomas Ph.D Self Board Member 000 0000
Gilles Nobécourt Andera Partners Board Member 000 0000
Jean-François Prost MD GamaMabs Pharma Chief Medical and Scientific Officer, Board Member and Vice President of Research and Development and Strategy 000 0000
Jean-Michel Petit Institut Régional de Développement Industriel Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

GamaMabs Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GamaMabs Pharma Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Andera Partners PE/Buyout Minority 000 0000 000000 0
Institut Régional de Développement Industriel Venture Capital Minority 000 0000 000000 0
Alto Invest Asset Manager Minority 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
CDC Enterprises PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »